Journal of neurology, neurosurgery, and psychiatry
-
J. Neurol. Neurosurg. Psychiatr. · Nov 2004
Multicenter Study Clinical TrialThe beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles.
To study the efficacy, safety, and incidence of BtxA antibody formation with repeated treatments with BtxA in post-stroke upper limb muscle spasticity. ⋯ BtxA at a dose of 1000 units Dysport was efficacious in the symptomatic treatment of post-stroke upper limb spasticity. The study suggests that this effect can be maintained with repeated injections for up to at least three treatment cycles, with duration of effect per cycle of between 12 and 20 weeks. BtxA was safe in the dose used in this study and did not induce the formation of detectable levels of neutralising BtxA antibodies.
-
J. Neurol. Neurosurg. Psychiatr. · Nov 2004
Multicenter Study Clinical TrialLong term effect (more than five years) of intrathecal baclofen on impairment, disability, and quality of life in patients with severe spasticity of spinal origin.
To evaluate long term change in impairment, disability, and health related functional status in patients with severe spasticity who received intrathecal baclofen. ⋯ Long term administration of intrathecal baclofen delivered by an implanted programmable pump resulted in improved clinical efficacy but not in improvement in disability or perceived health status.